Rapport Therapeutics Insider James Healy Buys $20.4M of Stock
James Healy bought 969,480 shares of Rapport Therapeutics, Inc. at $21.00 a share, worth $20.4M in total on Oct 28, 2026. Shares held after the trade: 25,267 (+37.8%).
Rapport Therapeutics Director Ramiro Sanchez Buys $98.5K of Stock
Ramiro Sanchez, Director, bought 3,600 shares of Rapport Therapeutics, Inc. at $27.35 a share, worth $98.5K in total on Oct 23, 2026. Shares held after the trade: 3,600.
Rapport Therapeutics Director Paul M. Silva Buys $99.6K of Stock
Paul M. Silva, Director, bought 3,680 shares of Rapport Therapeutics, Inc. at $27.07 a share, worth $99.6K in total on Oct 22, 2026. Shares held after the trade: 3,680.
Rapport Therapeutics Director Wendy B. Young Buys $100K of Stock
Wendy B. Young, Director, bought 3,789 shares of Rapport Therapeutics, Inc. at $26.39 a share, worth $100K in total on Oct 22, 2026. Shares held after the trade: 13,289 (+39.9%).
Rapport Therapeutics Director Steven M. Paul Buys $974K of Stock
Steven M. Paul, Director, bought 35,714 shares of Rapport Therapeutics, Inc. at $27.28 a share, worth $974K in total on Oct 22, 2026. Shares held after the trade: 77,380 (+85.7%).
Rapport Therapeutics Director John Maraganore Buys $249K of Stock
John Maraganore, Director, bought 9,411 shares of Rapport Therapeutics, Inc. at $26.38 to $26.92 a share (average $26.45) in 2 transactions, worth $249K in total on Oct 22, 2026. Shares held after the trade: 9,411 (+14.2%).
Rapport Therapeutics CFO Troy A. Ignelzi Buys $144K of Stock
Troy A. Ignelzi, CFO, bought 5,500 shares of Rapport Therapeutics, Inc. at $26.10 a share, worth $144K in total on Oct 21, 2026. Shares held after the trade: 15,500 (+55.0%).